Formosa Pharmaceuticals, Inc.’s Post

Come and visit our stand to get a report on the disruptive pre-clinical CROs that are out there - and to discuss M&A and growth strategies should you wish!

Exciting Updates from CPHI China 2024 As CPHI China 2024 concludes, heartfelt thanks go out to all involved - partners, sponsors, organizers, and participants. Your dedication and hard work ensured the event's success. Another successful year at CPHI - the leading global event uniting pharma professionals for over three decades! From fostering connections to inspiring partnerships, CPHI continues to champion innovation at the heart of the pharmaceutical industry. This year, our team had the privilege to attend the event held in the Shanghai China 2024. Our CEO  Dr. Santosh Joshi along with his team Mr. Sunil Bharti (Business Development Head) and Mr. Satyam Ghag, represented our company with enthusiasm and passion. They seized the opportunity to network, learn, and contribute valuable insights to the community. We believe in the power of collaboration and knowledge sharing. Our team not only gained valuable insights but also shared their own experiences, contributing to the collective growth of the industry. As we say goodbye to #CPHIChina 2024, We are now committed to staying connected with our industry peers. Let's continue to innovate, collaborate, and shape the future of pharma together! #CPHI #CPHIChina #China #pharma #Pharmaceuticals #clinical #clinicalreserch #Clinicaltrial #Clinical #pharmasource #drugs #drugsdevelopment #analysis #India #Indianpharma #medicine

Last week, Bourne attended #CPHINorthAmerica in Philadelphia to connect with thought leaders and professionals across our core areas of focus within #Pharma and #PharmaServices. Overall themes include a proactive approach, strategic focus, and adaptability of companies operating in the pharmaceutical and biotech industries. Here are our key takeaways: #CPHINA #CPHINA2024 #CPHI #BournePartners #InvestmentBanking

[#Healthcare] The Nov Santé team announces an investment in Oncodesign Services, a leading French player in pharmaceutical pre-clinical research led by Fabrice Viviani, PhD, alongside Elyan Partners. 🔬 This transaction occurs in the context of the acquisition of the Dutch company ZoBio , first milestone in the transformation of Oncodesign Services into an integrated drug discovery CRO. 🔎 Oncodesign Services is a major player in its sector, with core strengths in bioanalysis focusing on oncology and immuno-inflammation, and an extensive range of services, including medicinal chemistry, pharmaco-imaging and molecular radiotherapy. Based in Dijon and Les Ulis, with nearly 230 people, Oncodesign generated sales of €44 million in 2023. 🗣 “The outsourcing of pharmaceutical research services is a global trend. Maintaining France's and Europe's leading players in this field is vital to our healthcare sovereignty. This means supporting scientific expertise in drug discovery, the first link in the healthcare chain. We are very proud to support Oncodesign Services in its ambition to become a key player in drug discovery.” Arnaud Vincent, Managing Director – Healthcare 📰 Read more: https://lnkd.in/eu-jcHPU   #research #science #DrugDiscovery #DrugDiscoveryTechnology #pharmacy #biotech #CRO #oncology Asnen Cassam-Chenaï Samantha Schwartz Hugo Pergher Simon Mauclair Olivier MILLET Jean-François Félix Maxence de Vienne Guillaume Vacherand Davide Giacometti

KBI Biopharma's poster about its new afucosylated cell line can be seen in the first seconds of the video. A highly interesting topic to discuss with our expert Alexia Borgeat at booth 710 if you're developing an immuno-oncology antibody and are on the lookout to enhance your ADCC!

This is a very significant paper hightlighting the potential of this technology in pharmaceutical industry.

Great takeaways from CPhI Milan! 🇮🇹 Packed with insights on the latest pharmaceutical innovations and fruitful new partnerships formed. We're energized to bring these opportunities to life! #CPhI #Milan #PharmaceuticalIndustry

🌟 Columbus Venture Partners brings exciting news and updates about our portfolio companies! 🌟 🏆 Co-Founder and Chief Scientific Officer of Vivet Therapeutics, Gloria Gonzalez-Aseguinolaza has been honored with the prestigious Rosalind Franklin Society (RFS) Special Award in Science 🔬 for her remarkable contributions and dedication to advancing scientific knowledge. 🚀 Artax Biopharma Inc has updated information on their candidate pipeline and the progress they are making in the development of AX-158 and AX-194 for #autoimmunediseases, #psoriasis, and #atopicdermatitis. Learn more here: https://lnkd.in/d_RrncBp 💡 Integra Therapeutics will receive up to €10.5 million from the European Commission for their advanced therapies platform #FiCAT through the #eicAccelerator program. ℹ More information: https://lnkd.in/dB_WXPqD 🔬 QUATRE LAB explains the benefits of outsourcing to CROs for the bio-pharmaceutical industry, addressing the complexities of rare diseases more effectively and ensuring innovative treatments reach patients faster. 🔍 To read the full article, visit: https://lnkd.in/d4xbxmQc 𝗖𝗼𝗻𝗴𝗿𝗮𝘁𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝗮𝗹𝗹 𝗼𝗳 𝘆𝗼𝘂! #biotech #innovation #healthcare #pharmaceuticals #research #ColumbusVP #investment #AdvancedTherapies #GeneTherapy #GeneWriting #CRISPR #clinicaltrials #immunology

NEWS! CPHI Japan 2024 (17-19 April) will see a 20+% year-on-year rise, with a record attendance of an expected 20,000 attendees as the country undergoes a post pandemic boom in pharma – with biologics and tides manufacturing expected to grow quickly. The event is widely seen as a barometer of overall health in the country’s pharma industry and in light of significant R&D growth, Tides will collaborate with CPHI Japan to introduce a free conference. The increased interest is attributed to a proactive regulatory framework and the country’s strong base of peptide and oligonucleotide chemistry and synthesis. Prof Hiroaki Suga of the University of Tokyo will present his predictions on the potential of mRNA and peptides at the event. https://lnkd.in/d3rvs-SY #news #tides #manufacturing #peptides #oligonucleotides #mediapartnership #pharma

https://lnkd.in/e2p6SFgk 🚀 Exciting News Alert! 🚀   We're thrilled to announce the launch of the Liver Ring Trial, a groundbreaking collaboration between TissUse GmbH and ESQlabs GmbH (a computational model expert), UCB, a global biopharmaceutical company and initiators of the ring trial, and five other pharmaceuticals (Orion Corporation, Sanofi-Aventis Recherche & Développement, Technologie Servier France/Biologie Servier, AstraZeneca AB, and Boehringer Ingelheim), set to revolutionize drug safety assessment! 👉 Press Release: https://lnkd.in/e2p6SFgk Novel Liver Ring Trial Set to Revolutionize Drug Safety Assessment We're embarking on a mission to validate the reproducibility and accuracy of Liver Micro-Physiological Systems (MPS) in predicting drug-induced liver injury (DILI) and intrinsic clearance. This marks a paradigm shift in non-clinical drug assessment.  To validate a tool to be used for the evaluation of both drug safety and metabolism. "Our microfluidic platform is not just about simulating liver functions; it's about creating a more holistic organ-to-organ interaction, thereby offering a more accurate representation of human physiology," stated Dr. Reyk Horland, CEO at TissUse. With the guidance of regulatory bodies like the European Medicines Agency (EMA) and the EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) of the European Commission’s Joint Research Centre (JRC), we aim to provide more confidence to use MPS data for regulatory submission and, ultimately, support decision making. Join us in shaping the future of drug safety assessment! #LiverRingTrial #DrugSafety #Innovation #PreclinicalResearch #NAMs #OrganOnChip